Denali Therapeutics’ (DNLI) Buy Rating Reaffirmed at HC Wainwright

Denali Therapeutics (NASDAQ:DNLI)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $90.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 204.57% from the stock’s previous close.

DNLI has been the subject of a number of other reports. Citigroup increased their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Bank of America increased their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Wedbush dropped their price target on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Finally, Jefferies Financial Group boosted their target price on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $38.90.

Denali Therapeutics Price Performance

NASDAQ:DNLI opened at $29.55 on Thursday. The business’s fifty day moving average price is $27.57 and its 200 day moving average price is $23.36. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $32.13.

Insider Buying and Selling

In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares in the company, valued at $6,529,495.83. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the transaction, the director now owns 29,096 shares of the company’s stock, valued at $844,656.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the sale, the chief executive officer now owns 235,807 shares of the company’s stock, valued at $6,529,495.83. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

Several large investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in shares of Denali Therapeutics during the first quarter worth approximately $147,000. ClariVest Asset Management LLC raised its stake in Denali Therapeutics by 18.8% during the 1st quarter. ClariVest Asset Management LLC now owns 47,748 shares of the company’s stock valued at $980,000 after purchasing an additional 7,568 shares during the last quarter. Swiss National Bank boosted its holdings in Denali Therapeutics by 0.7% in the 1st quarter. Swiss National Bank now owns 218,200 shares of the company’s stock valued at $4,477,000 after purchasing an additional 1,500 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in Denali Therapeutics in the 1st quarter worth $4,330,000. Finally, Headlands Technologies LLC acquired a new stake in Denali Therapeutics in the 1st quarter worth $88,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.